[Information Sharing] National Report on Major Animal Epidemics for July 2025

Source: Animal Husbandry and Veterinary Bureau, Ministry of Agriculture and Rural Affairs

In July 2025, a total of 24 major animal epidemics of categories I, II, and III were reported nationwide, affecting 142,754 animals (heads/birds/individuals/horses) and resulting in 9,843 deaths. Among these, one category I epidemic was reported, involving 215 animals (heads/individuals) with 209 deaths. Sixteen category II epidemics were reported, affecting 23,707 animals (heads/birds/individuals/horses) and causing 3,340 deaths; the top three diseases in terms of reported cases were porcine epidemic diarrhea, duck plague, and brucellosis, accounting for 85.48% of all category II epidemic reports. Seven category III epidemics were reported, affecting 118,832 animals (heads/birds/individuals/horses) and resulting in 6,294 deaths; the top three diseases in terms of reported cases were coccidiosis in chickens, swine influenza, and pasteurellosis, accounting for 98.75% of all category III epidemic reports.

Note: The statistical data in this table are derived from reports submitted by provinces, autonomous regions, municipalities directly under the central government, and the Xinjiang Production and Construction Corps on outbreaks of Category I, II, and III major animal epidemics.

For animal disease testing reagents, please choose the Weiboxin brand.

Be aware of Weiboxin Bio All products of!

Official consultation phone numbers: 020-82298089 / 135 3988 6748, Ms. Dai

Overseas Service Hotline (Mobile/WhatsApp/WeChat): +86 18902342201

Email: sara@viuick.com

Guangzhou Weiboxin Biotechnology Co., Ltd. is a provincial-level “Little Giant” high-tech enterprise specializing in the forward R&D, manufacturing, sales, and technical services of diagnostic reagents for infectious diseases. The company is also recognized as a “Contract-Honoring and Credit-Keeping Enterprise” by Guangdong Province and a “Provincial Intellectual Property Demonstration Unit.” It serves as an industry–university–research collaboration base for Guangdong Food and Drug Vocational College and holds a standing directorship on the Veterinary Diagnostic and Biological Products Committee of the Guangdong Society of Animal Husbandry and Veterinary Medicine. Furthermore, it has been designated as an innovative, high-potential enterprise by multiple research institutions, including the Entrepreneurship College of Jinan University in Guangdong Province, and has been awarded the titles of “Specialized, Refined, Distinctive, and Innovative” enterprise at both municipal and provincial levels. The company has received the “Most Investment-Valuable Enterprise” award and the annual title of “ASF and Swine Disease Testing Service Provider,” and has obtained the approval number for veterinary drug products from the Ministry of Agriculture and Rural Affairs. : Veterinary Drug Registration No. 191438923 (Fluorescent PCR Detection Kit for African Swine Fever Virus) 、 Veterinary Drug Registration No. 191438213 (Porcine Reproductive and Respiratory Syndrome Virus ELISA Antibody Detection Kit) 、 Veterinary Drug Registration No. 191438875 (Classical Swine Fever Virus Blocking ELISA Antibody Detection Kit) and Veterinary Drug Registration No. 191438851 (Porcine Circovirus Type 2 ELISA Antibody Detection Kit) The company has been recognized with the Excellence Award in the Growth Category of the Biopharmaceutical Industry at the 11th China Innovation and Entrepreneurship Competition, as well as the Provincial Second Prize in the Growth Category of the Nanotechnology Industry Technology Competition under the Science and Technology Innovation and Entrepreneurship Contest. Furthermore, it secured the National Third Prize in the Growth Category at the National Finals of the Nanotechnology Industry Technology Innovation Special Competition within the China Innovation and Entrepreneurship Competition. The company has also consecutively received the A-Level Tax Credit Certificate, the Four-Star Trademark and Brand Certification, and the Two-Integration Management System Assessment Certificate each year. In addition, it holds ISO 9001 International Quality Management System Certification, ISO 14001 International Environmental Management System Certification, and GMP Certification from the Ministry of Agriculture. Since its establishment, the company has been granted a total of 24 patents, including 5 invention patents, 15 utility model patents, and 4 design patents, along with more than ten trademarks.

The company boasts robust technical capabilities and a world-class team of professionals, including dozens of masters, doctors, and returnees who studied abroad, as well as numerous senior-title technical experts. Currently, the company’s primary focus is on the R&D of molecular diagnostic reagents. Its core R&D team has developed more than 600 products spanning molecular diagnostics and immunoassays, including public-health–oriented fluorescent PCR test kits, animal disease–control fluorescent PCR test kits, clinical and research-grade fluorescent quantitative PCR kits, and transgenic identification test kits (ZL2006). The company has established a nationwide distribution network covering over ten major cities, such as Beijing, Shanghai, Hangzhou, Nanjing, Wuhan, Xi’an, Yunnan, Chongqing, Chengdu, Guizhou, Lanzhou, Zhengzhou, Qingdao, Inner Mongolia, and Xinjiang. Moreover, its products are now exported to numerous overseas markets, including the United Arab Emirates, Oman, Egypt, Pakistan, Paraguay, Poland, Colombia, Kazakhstan, Mongolia, Bangladesh, Myanmar, Mexico, Nigeria, Saudi Arabia, Spain, Armenia, India, Indonesia, Vietnam, and Cambodia, providing high-quality products and services to customers worldwide.

Looking ahead, Weiboxin will remain steadfast in its commitment to continuously enhance product quality and service standards. Leveraging a rapid and efficient research platform and abundant biomedical resources, we will conduct extensive and in-depth R&D and scientific research in the biomedical field, thereby contributing to human health and advancing life sciences. Quality is our lifeline; innovation is our soul. Upholding this guiding principle, we will relentlessly strive to become the premier supplier of rapid diagnostic reagents and instruments.